Feasibility and Safety of Insulin Pump Therapy in Children Aged 2 to 7 Years With Type 1 Diabetes: A Retrospective Study

Berhe, Tseghai; Postellon, Daniel C.; Wilson, Bruce E.; Stone, Roberta

doi:10.1542/peds.2005-2363

Cited by 38 publications

(36 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…167,168 Several studies described intensive training/ education of participants and their families. 101,140,144,146,147,152,[154][155][156][157][158][159][160][161][162][164][165][166][170][171][172][173][174] Some training programmes included the use of a dummy saline pump. 154,157,158,171 Initiation of pump therapy involved a period of admission to clinic or hospital in a few studies.…”

Section: Education and Support For Csiimentioning

confidence: 99%

“…154,157,158,171 Initiation of pump therapy involved a period of admission to clinic or hospital in a few studies. 152,158,171 Intensive ongoing support was often provided, including initial frequent visits and telephone contact, 152,156,158,161,165,166,172 and 24-hour nurse on call or telephone support. 140,164,166,174 …”

Section: Education and Support For Csiimentioning

confidence: 99%

“…Continuation rates of 100% were reported in two studies: in adults/mixed age groups 144, 163 and five studies in adolescents and children. 154,156,159,164,165 A variety of reasons for discontinuing CSII were reported in 12 studies (Tables 10-12 …”

Section: Continuation Ratesmentioning

confidence: 99%

“…156 165 reported that 76% of patients had HbA 1c levels of < 8.5% after CSII compared to 35% before.…”

Section: Raile Et Al (2002)mentioning

confidence: 99%

See 3 more Smart Citations

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

Cummins

Royle²,

Snaith³

et al. 2010

Health Technol Assess

184

155

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Section: Education and Support For Csiimentioning

confidence: 99%

Section: Education and Support For Csiimentioning

confidence: 99%

Section: Continuation Ratesmentioning

confidence: 99%

“…156 165 reported that 76% of patients had HbA 1c levels of < 8.5% after CSII compared to 35% before.…”

Section: Raile Et Al (2002)mentioning

confidence: 99%

See 2 more Smart Citations

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

Cummins

Royle²,

Snaith³

et al. 2010

Health Technol Assess

184

155

View full text Add to dashboard Cite

show abstract

“…An increasing number of studies have shown a beneficial effect on glycaemic control with CSII compared with MDI (52)(53)(54)(55)(56)(57). In addition, observational trials in children have shown a decrease in the rate of severe hypoglycaemic episodes with CSII, despite decreasing HbA1c values (55,(58)(59)(60).…”

Section: Insulin Pumpsmentioning

confidence: 99%

Insulin delivery by injection in children and adolescents with diabetes

Hanås¹,

Beaufort²,

Hoey³

et al. 2011

Pediatric Diabetes

View full text Add to dashboard Cite

Past, present, and future of insulin pump therapy: better shot at diabetes control

Sherr

Tamborlane

2008

Mount Sinai J Medicine

View full text Add to dashboard Cite

With the advent of continuous subcutaneous insulin infusion (CSII) therapy and the findings of the Diabetes Control and Complications Trial (DCCT) the management of type 1 diabetes has changed drastically. Over the past 30 years since its development, the effectiveness of CSII as compared to other modes of intensive treatment has been assessed. Additionally, improvements in pump delivery systems have been made. Herein the findings of the studies on pump therapy will be reviewed. Selection criteria of patients for pump use and how to initiate pump therapy will be presented. Finally, newer findings on continuous glucose sensors will be discussed as the next era of pump therapy continues to focus on the goal of developing an artificial pancreas. Keywords Type 1 Diabetes; Continuous Subcutaneous Insulin Infusion (CSII); insulin pumps; multiple daily injections (MDI) Dawn of Pump TherapyContinuous subcutaneous insulin infusion (CSII) pump therapy was introduced to treat patients with type 1 diabetes in the late 1970's (1,2). Until then, care of individuals with type 1 diabetes was crude, involving one or two daily injections of NPH and regular insulin of animal origin that was not purified, adjusting insulin doses based on urinary glucose excretion, and dietary counseling focused on limiting simple sugars and maintaining fixed macronutrient intake at each meal. Due to the limitations of this regimen and fear of hypoglycemia, particularly in children, glucose levels often averaged over 300mg/dL. It is also important to remember that at that time, a causal relationship between poor glycemic control and the development of complications was suspected but not yet proven. Thus, it is not surprising that the demonstration that CSII could provide a more physiologic method of insulin replacement in T1DM was enthusiastically received (1-4). Self-monitoring of blood glucose (SMBG), hemoglobin A1c assays (HbA1c), and purified insulin preparations were also introduced in the late 1970's and the basal bolus approach utilized for CSII was adapted for use in multiple daily injection (MDI) regimens. These advances made intensive treatment of T1DM possible and set the stage for the Diabetes Control and Complications Trial (DCCT) that was launched in 1983.Intensive therapy did not come without a price. An increased risk of severe hypoglycemia, due in part to reductions in counterregulatory hormone responses to hypoglycemia, was demonstrated (5,6). This acquired inability to symptomatically identify low blood glucose Address for Corresponding author: Department of Pediatrics, Yale University School of Medicine, P.O. Box 208064, New Haven, CT 06520-8064, 203-785-4279 (tel), 203-737-2829 (fax) NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript levels due to repeated episodes of mild hypoglycemia was named "hypoglycemia-associated autonomic failure" (7) and made patients even more vulnerable to severe hypoglycemic events. Consequently, the need to solve the puzzle of the relationship between hyperglycemia a...

show abstract

Feasibility and Safety of Insulin Pump Therapy in Children Aged 2 to 7 Years With Type 1 Diabetes: A Retrospective Study

Abstract: Continous subcutaneous insulin infusion therapy in young children with type 1 diabetes is a safe, effective and superior alternative to a twice-a-day insulin regimen.

Cited by 38 publications

References 37 publications

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

Insulin delivery by injection in children and adolescents with diabetes

Past, present, and future of insulin pump therapy: better shot at diabetes control

Contact Info

Product

Resources

About